This interactive case-based activity on type 2 diabetes will review therapy intensification, application of the SGLT2 inhibitors, and novel combination regimens. The cases, led by Dr. George Bakris, allow you to make clinical decisions throughout and provide you with personalized education recommendations.

Overview of Virtual Clinic Activity

Diabetes continues to have a significant impact on morbidity and mortality in the United States, and is an ongoing treatment challenge for primary care providers who lack confidence with treatment intensification including newer agents and combination therapies. Further, approaches to improved adherence and lifestyle modification through shared-decision making continue to evolve with the goal of improving quality of care.

Release Date: November 24, 2015
Expiration Date: November 24, 2016

Target Audience

This educational activity is designed for primary care physicians (internal medicine, family practice MD/DOs) and nurses involved in the management of patients with Type 2 Diabetes (T2DM).

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Review selection of therapies and combination regimens for diverse T2DM patients requiring intensification to achieve established goals for glycemic control
  • Compare and contrast the safety, efficacy, and tolerability of available and emerging treatment regimens for T2DM
  • Discuss the role of SGLT2 inhibitors in the management of T2DM


George Louis Bakris, MD


Professor of Medicine and Director, ASH
Comprehensive Hypertension Center
The University of Chicago Medicine
Chicago, IL


This CME activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. Indiana University School of Medicine requires the speaker to disclose that a product is not labeled for the use under discussion. The provider’s documentation of common practices that make the disclosure requirement known to faculty demonstrates compliance with ACCME guidelines.

Faculty Disclosures

George Louis Bakris, MD (Chair):

Investigator-initiated Grant/Research Support: Medtronic, Takeda (direct funding to University of Chicago)

National Clinical Trial Principal Investigator Studies: Medtronic, Relypsa, Bayer

Consultant: Takeda, AbbVie, CVRx, Janssen, Eli Lilly, Boehringer-lngelheim, Medtronic, AstraZeneca, Novartis, GSK, Bayer, Daiichi-Sankyo

Staff and Reviewer Disclosures

ACHL and Indiana University School of Medicine staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

lode more

CME Information


Accreditation Statement

Indiana University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Indiana University School of Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

While it offers CME credits, this activity is not intended to provide extensive training or certification in the field.

Instructions for Participation and Credit

Participation in this activity is free. To receive credit, participants are required to complete the pre-test, online activity, evaluation, and achieve 80% on the post-test. A certificate will be immediately available.

If you have any questions relating to the accreditation of this activity, please contact Vanessa Senatore, Phone: 773-714-0705 ext. 189, or


This activity is planned and implemented by Indiana University School of Medicine and the Academy for Continued Healthcare Learning (ACHL)


This CME activity is supported by an educational grant from Janssen Pharmaceuticals, Inc., administered by Janssen Scientific Affairs, LLC.



Hardware and Software Requirements

This site is best viewed with an HTML5 compatible browser, this list includes the versions of Mircrosoft Internet Explorer, Mozilla Firefox, Google Chrome, and Apple's Safari. You can visit the independent (3rd party) site to determine if you have the latest version of your browser. Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. That software may be: Adobe Flash, Apple Quicktime, Adobe Acrobat, Microsoft Powerpoint, Windows Media Player, and Real Networks Real One Player.


This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

lode more


Curriculum Education

Avoiding Clinical Inertia for Improved Outcomes in Type 2 Diabetes: The Application of SGLT2 Inhibitors.
Download Slides: upload/T2DM-Curriculum-Education-Slides.pdf

Patient-centered Treatment Regimens in Newly Diagnosed Type 2 Diabetes

Novel Therapies and Combinations for Second-line Therapy in Type 2 Diabetes

Clinical Resources

American Diabetes Association. Standards of medical care in diabetes 2015. Diabetes Care. 2015;38(suppl 1): S1-S94. Available at: entypa/ STANDARDS OF MEDICAL CARE IN DIABETES 2015.pdf

American Diabetes Association. Standards of medical care in diabetes-2015 abridged for primary care providers. Clin Diabetes. 2015;33(2):97-111. Available at: content/33/2/97.full.pdf

Garber AJ, Abrahamson MJ, Barzilay JI, et al. AACE/ACE comprehensive diabetes management algorithm 2015. Endocr Pract. 2015:1-28. Available at: aace_algorithm.pdf

Handelsman Y, Bloomgarden ZT, Grunberger G, et al. American Association of Clinical Endocrinologists and American College of Endocrinology - clinical practice guidelines for developing a diabetes mellitus comprehensive care plan-2015. Endocr Pract. 2015;21 Suppl 1:1-87. Available at: /pdf/10.4158/EP15672.GLSUPPL

Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38(1):140-9. Available at: content/38/1/140.full.pdf+html

Patient Education

American Diabetes Association. Type 2 diabetes basics. Available at: diabetes-basics/type-2/

National Diabetes Education Initiative. Patient handouts. Available at: patienteducation.aspx


May I pause the activity in the middle of a case and return at a later time to complete it?
Users can pause the activity at any time during viewing. If you exit the activity, the program will resume from the beginning upon reentry. Users do not, however, need to complete a pre or post test more than once.
Who do I contact if I have technical difficulties with this online portal?
Please contact Vanessa Senatore, Program Director. Email:
Phone: (773) 714-0705 x 189
Is a mobile option of the activity available?
Yes, this CME activity is available on an iPad and Android tablet.


If you have questions about this program, please contact:

Vanessa Senatore

Call Us

Phone: 773-714-0705 x189